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Background: Alzheimer’s disease (AD) is a severe neurodegenerative disease for which there is currently no
effective treatment. The purpose of this study was to investigate whether repeated electroacupuncture (EA)
stimulation would improve cognitive function and the pathological features of AD in amyloid precursor protein
(APP)/presenilin 1 (PS1) double transgenic mice.
Methods: Cognitive function of APP/PS1 double transgenic mice was assessed using the Morris water maze test
before and after EA treatment. Levels of amyloid β-peptide (Aβ) deposits in the hippocampus and cortex were
evaluated by immunofluorescence, western blot and enzyme-linked immunosorbent assay. Expression of
brain-derived neurotrophic factor (BDNF) was also examined by immunofluorescence and western blot. The
neurogenesis was labeled by the DNA marker bromodeoxyuridine.
Results: EA stimulation significantly ameliorated the learning and memory deficits of AD mice by shortening
escape latency and increasing the time spent in the target zone during the probe test. Additionally, decreased Aβ
deposits and increased BDNF expression and neurogenesis in the hippocampus and cortex of EA-treated AD mice
were detected. The same change was detected in wild-type mice after EA treatment compared with wild-type mice
without EA treatment.
Conclusions: Repeated EA stimulation may improve cognitive function, attenuate Aβ deposits, up-regulate the
expression of BDNF and promote neurogenesis in the APP/PS1 double transgenic mice. This suggests that EA may
be a promising treatment for AD.
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Alzheimer’s disease (AD) is one of the most common
neurodegenerative diseases. Its main clinical manifesta-
tions include dementia, memory loss, personality disor-
ders and language problems. The global prevalence of
dementia was estimated to be as high as 24.2 million by
2005, and about 70% of these cases were attributed to
AD [1]. Prevalence is predicted to reach 80 million
worldwide by 2040 [2]. Confronted with such a large
number of people suffering from AD, the currently avail-
able treatments for the disease are limited and without* Correspondence: lxiong@fmmu.edu.cn; wangqiang@fmmu.edu.cn
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reproduction in any medium, provided the orcurative effects. Therefore, identifying effective and safe
treatment with clear fundamental mechanisms is ur-
gently needed.
The pathology of AD is generally accepted as being
characterized by the abnormally abundant deposition of
amyloid plaques, neurofibrillary tangles, and selective
neuronal loss in the frontal and temporal cortices, as
well as the hippocampus of brain. The accumulation of
amyloid β-peptide (Aβ) plays the most important role in
the pathogenesis of AD. A wealth of evidence has indi-
cated that Aβ1-42 deposits participate in the process of
neuron loss and lead to the occurrence of dementia in
AD patients.
AD is a multifactorial disease, and a decrease in
neuro-regenerative capacity is an important factor in thehis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and neurofibrillary tangles [3]. Numerous studies have
provided powerful evidence that the decline of hippo-
campal neurogenesis participates in the development of
AD and induces impairment of learning and memory
[4]. Several studies have indicated that brain-derived
neurotrophic factor (BDNF) is an important factor for
promoting neurogenesis in the adult central nervous sys-
tem under physiological or pathological conditions [5,6].
Moreover, some clinical studies have revealed that the
level of BDNF expression is significantly decreased in
the hippocampus and some cortical areas of AD patients
[7,8]. These data suggest that up-regulation of BDNF
and promotion of neurogenesis would be a promising
target for AD treatment.
Electroacupuncture (EA), a traditional Chinese medi-
cine treatment that stimulates certain acupoints, has
been shown to induce significant neuroprotective effects
in various kinds of central nervous system diseases, as
well as improve neuroethology [9-11]. The mechanism
for EA improving neurological deficits in ischemic injury
is proven to be through the promotion of neurogenesis
[12]. EA has also been proven to enhance BDNF activa-
tion in the dentate gyrus in rats [13]. However, whether
EA stimulation is effective for AD still remains unclear.
In the present study, we investigated whether EA
treatment could ameliorate cognitive impairment and at-
tenuate Aβ deposits, and the effect of EA treatment on
BDNF expression and neurogenesis in the amyloid pre-




We used an APP/PS1 double Tg C57BL/6 J mouse
model, which could effectively simulate the pathological
features of AD patients. We used this model to investi-
gate the effect of EA treatment on AD mice. Male APP/
PS1 double Tg mice (2-months old) were purchased
from Beijing HFK Bioscience Co. LTD (Beijing, China)
and randomly divided into two groups: an APP/PS1
group (APP) and an EA treatment APP/PS1 group (APP
+ EA). Normal male C57BL/6 J mice (2 months old)
were obtained from the Experimental Animals Center of
the Fourth Military Medical University (Xi’an, China)
and randomly divided into two groups: a control group
(Con) and an EA treatment control group (Con + EA).
Animals were housed under controlled temperature
(25°C), 12-hour light/dark cycles and allowed free access
to water and food. All experiments were carried out ac-
cording to the Guidelines for Animal Experimentation of
the Fourth Military Medical University. The experimental
protocol was approved by the Ethics Committee for Animal
Experimentation, and was performed according to theGuidelines for Animal Experimentation of the Fourth
Military Medical University and to the National Institute of
Health Guide for the Care and Use of Laboratory Animals.
EA treatment
In line with our previous studies, we performed EA
treatment at the “Baihui (GV20)” acupoint with an in-
tensity of 1 mA and frequency of 2/15 Hz for four weeks
for total 20 days (30 min/day, 5 days/week) [10,14]. We
used an EA instrument (Hwato, model No. SDZ-V,
Suzhou Medical Instruments Co, Ltd, Suzhou, China)
and selected the dense-sparse wave type. During EA
treatment, we maintained the rectal temperature of all
animals at 37.0 ± 0.5°C and we provided inhaled oxygen
by facemask at a flow rate of 1 L/min. The animals in
control group received no treatment.
Morris water maze test
Following the methods previously described, we used
the Morris water maze (MWM) test to evaluate learning
and memory impairment in each group in this experi-
ment. We evaluated the Morris water maze test at 7
months and 10 months (before EA treatment), and at 11
months (immediately after EA treatment). The apparatus
consisted of a circular pool (120 cm diameter × 50 cm
height) with a black inner wall, which was subdivided
into four equal quadrants and filled with water (25°C) to
the depth of 30 cm. An escape platform (10 cm diam-
eter) was placed in one of the quadrants (the target
quadrant) and submerged approximately 2 cm below the
surface of the water. Mice were released into the water
facing the wall of the pool. The test contained a platform
trial that measured the animal’s spatial acquisition ability
and a spatial probe test that assessed memory. On the
first day, the mice in each group performed four plat-
form trials with the platform submerged in water in the
same place each time. They then performed four train-
ing trials per day for five days. Finally, 24 hours after the
5th day, a probe test, where the platform was removed,
was performed. All the data, including the swim path
and the swim time, were measured by an automated
analyzing system (Dig-Behav, Jiliang Co., Ltd., Shanghai,
China).
Sample preparation and double-label
immunofluorescence assays
Immunofluorescence was used to evaluate levels of Aβ
deposits and BDNF expression in the hippocampus and
cortex of each group. At first, to remove the blood and
fix the brain tissues, the Tg mice were deeply anesthe-
tized with 0.8% pentobarbital sodium and perfused with
physiological saline, followed by 4% (v/v) ice-cold para-
formaldehyde in PBS (pH = 7.4). Brain tissues were then
harvested and postfixed for 2 hours in the same fixative
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tions. Coronal Sections 12 μm in thickness were cut
using a cryostat and block with PBS containing 0.3% (v/
v) Triton X-100 and 3% (v/v) normal goat serum. To
verify the success of the AD model building, the tissue
sections were incubated overnight with rabbit anti-Aβ
primary antibodies (1:400, Cell Signaling Technology,
Inc. Danvers, MA, USA) followed by the anti-rabbit Cy3
tagged secondary antibodies (1:200; CWBIO, Beijing,
China). To investigate the effect of EA on Aβ deposits
and BDNF expression in the brain, immunofluorescence
was conducted. The sections were incubated with the
first antibody of rabbit anti-BDNF (1:200, Beijing Biosyn-
thesis Biotechnology Co., Ltd, Beijing, China) or rabbit
anti-Aβ antibody (1:400, Cell Signaling Technology, Inc.
Danvers, MA, USA) followed by the anti-rabbit Cy3
tagged secondary antibodies (1:200; CWBIO, Beijing,
China). The sections were mounted with 50% glycerol
for examination under a fluorescence microscope. Im-
ages were observed and captured with a co-focal laser
microscope (FV1000; Olympus BX51; Tokyo, Japan).
Western blot analysis
Animals of each group were anesthetized with sodium
pentobarbital (100 mg/kg, i.p.) and sacrificed immediately
by decapitation. Brain tissues were then removed, weighed
and homogenized in RIPA buffer (Beyotime P0013C,
Haimen, Jiangsu, China) plus protease inhibitors. A BCA
Protein assay kit (Beyotime P0012S, Haimen, Jiangsu,
China) was used to determine the protein concentrations
of each sample; 40ug protein samples were separated by
15% SDS-PAGE. The proteins were then transferred onto
polyvinylidene difluoride membrane. After blocking with
3% nonfat milk, membranes were incubated with the fol-
lowing primary antibodies: rabbit anti-BDNF monoclonal
antibody (1:100, Beijing Biosynthesis Biotechnology
Co., Ltd, Beijing, China), rabbit anti-β-actin (1:10000,
Epitomics, Inc., P60709), and rabbit anti-Aβ (1:400,
Cell Signaling Technology, Inc. Danvers, MA, USA).
Subsequently, membranes were incubated for 1 hour at
room temperature with secondary antibody of anti-
rabbit HRP-conjugated IgG (1:20000, CWBIO, Beijing,
China). Labeled protein was detected using chemilu-
minescence reagents (ECL; Amersham Bio-sciences,
Little Chalfont, Buckinghamshire, UK) and the band
intensity was analyzed (Alpha Innotech).
Quantification of Aβ1-42 level by ELISA
Levels of soluble Aβ1-42 in the hippocampus and cor-
tex of Tg mice were determined with sandwich
enzyme-linked immunosorbent assay (ELISA), using
mouse β-Amyloid (1–42) ELISA kit (Westang Ltd,
Shanghai, China). According to the manufacturer’s in-
struction, brain tissues were homogenized in RIPAbuffer (Beyotime P0013C, Haimen, Jiangsu, China) and
centrifuged at 27,000 × g at 4°C for 30 min to obtain
the supernatants. Then, the standards and samples
which were mixed with specific first antibody in
duplicate were added to the microtiter wells. HRP-
conjugated secondary antibody was added to the plates
for 1 h at room temperature after extensive washing,
followed by chromogen for 15–30 min. The enzymatic re-
action was then terminated by addition of a stop solution
(2 N H2SO4). Optical density (OD) was read at 450 nm
within 30 min on a microplate spectrophotometer
(Denley Dragon Wellscan MK 3). Concentrations were
calculated according to the standard curve.
BrdU staining
The newly born neurons were labeled by DNA marker
Bromodeoxyuridine (BrdU) (Sigma, St. Louis, MO,
dissolved in 0.9% NaCl). BrdU was administered intra-
peritoneally at a concentration of 100 mg/kg/day by
injection for seven consecutive days. And the first ad-
ministration was at the last 2 rest day of 4th cycle of the
electroacupuncture. To label differentiated neurons in
the hippocampus and cortex, 11-month-old Tg mice
APP, APP + EA and nontransgenic mice Con, Con + EA
(n = 5 each) were sacrificed 28 days after the last injec-
tion of BrdU. The mice were then anesthetized and
perfused with phosphate-buffered saline following by
4°C 4% paraformaldehyde. The brain was removed and
postfixed in buffered 4% paraformaldehyde for 2 hours.
After being immersed in 20% and 30% sucrose solu-
tion, the brains were cut into 12 μm-thick coronal
sections.
To label the relative distribution of the new proliferat-
ing cells, BrdU +Nissl double staining was used. First,
sections of every group were incubated with 10% normal
goat serum in 0.1 M PBS 60 min at 37°C. The primary
antibodies Nissl (Abcam) and rat anti-BrdU (ab6326,
Abcam LTD., Hongkong, China) were used. After wash-
ing in PBS, the sections were incubated in secondary
antibody Biotinylated Goat Anti-body IgG antibody
(1:300, Vector, BA 9400), and the third antibody Cy3-
conjugeted streptavidin (1:800). For each group, brain
sections starting from the bregma −2.1 and ending at
the bregma −4.5 were selected for counting of the
BrdU(+) and Nissl(+) cells. The BrdU(+) and Nissl(+)
cells were calculated using a × 400 magnification in the
DG, CA1 regions.
Statistical analysis
SPSS 14.0 for Windows was used to conduct the statis-
tical analyses. Two-way analysis of variance (ANOVA)
with repeated measures was used for analyzing data
from the Morris water maze test. Other statistical tests
were performed using one-way ANOVA and Student’s
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sidered indicative of statistical significance. All date
are expressed as mean ± standard deviation (SD).
Results
Cognitive impairment and Aβ1-42 deposition presented in
the APP/PS1 mice
Transgenic mice, which imitated the most salient char-
acteristics of AD, were selected to simulate human
Alzheimer’s disease. The effectiveness of the Tg mouse
model to mimic AD was evaluated using a neurological
behavior test (Morris water maze test) and a pathology
test (immunofluorescence that specifically identified a
biomarker of AD) of 7-month-old and 10-month-old Tg
mice. Spatial learning and memory function perform-
ance were more severely damaged in the 7-month-old
group of double Tg mice than in the wild-type C57 mice;
this was evaluated by the platform trial and spatial probe
test of the Morris water maze test (Figure 1A, B) without
a significant difference in swimming speed (Figure 1C).
However, there was no significant difference between
the 7-month-old and 10-month-old Tg mice groups.
This indicated that the pathological features of APP/PS1
double Tg mice developed from at least 7 months and
remained stable.
Total Aβ deposits in the hippocampus and cortex were
detected by quantitative immunofluorescence in different
groups (Figure 1D). The Aβ level of the hippocampus and
cortex in the 10-month-old group was increased compared
with wild-type group.Figure 1 APP/PS1 mice demonstrated features of cognitive impairme
APP/PS1 mice showed longer latencies for reaching the platform in the Mo
swimming speeds among different groups were not significant different. (C
quadrant than 7-month-old and 10-month-old APP mice. (n = 6 in each gro
mice, total Aβ deposits in the hippocampus and cortex of 7-month-old anEA ameliorated cognitive impairment in APP/PS1
double Tg mice
We investigated the effects of EA stimulation on cogni-
tive function through use of the Morris water maze
(MWM) test. This test was conducted following the
procedure diagram shown in Figure 2A. As shown in
Figure 2B-C, escape latency indicated that the APP + EA
group had better cognitive performance than the APP
group. Cognitive impairment in the different groups was
confirmed in the probe trail, which showed that the
APP + EA group and the Con + EA group mice spent
more time in the target quadrant than their non
EA-treated counterparts (P < .05). This difference was
not attributable to the presence of motor deficits as the
four groups of mice exhibited similar swimming speeds
(Figure 2D). Taken together, the above results demon-
strate that EA stimulation significantly improved learn-
ing and memory functioning in both APP/PS1 Tg mice
and wild-type mice.
EA reduced brain Aβ1-42 deposition in APP/PS1 double
Tg mice
To investigate the effect of EA on Aβ1-42 deposition in
the hippocampus and cortex, three methods, including
immunofluorescence staining, ELISA and western blots,
were used. As shown in Figure 3A-B, Aβ1-42 staining
(red) was co-localized with neurons (Nissl staining,
green) in all studied regions. The APP + EA group exhib-
ited notable reductions in Aβ1-42 deposits compared
with the APP group, in both the hippocampus andnt seven months after birth. (A) 7-month-old and 10-month-old
rris Water Maze test than the wild-type mice. (B) The average
) During the probe trail, wild-type mice spent more time in the target
up) (*P < .05 from wild-type mice); (D) Compared with the wild-type
d 10-month-old APP mice were increased.
Figure 2 Electroacupuncture ameliorated cognitive impairments in APP/PS1 mice. (A) Schematic representation of the experiment
protocol. (B) Mice from the APP group showed longer latencies for reaching the platform than those from the APP + EA group. (C) The probe
test indicated that the time spent in the target quadrant was increased in the APP + EA group and Con + EA group compared with their non
EA-treated counterparts. (D) No significant difference was detected in average swimming speed among all the groups. (n = 6 in each group)
(*P < .05 vs. Con group; #P < .05 vs. APP group).
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posit of Aβ1-42 in normal-aged mice compared with the
Con group.
ELISA test results showed that the levels of Aβ1-42 de-
posits from the hippocampus and cortex in the APP + EA
group and the Con + EA group were significantly lower
than those in their non EA-treated counterparts (P < .05;
Figure 4A-B). At the same time, gray-scale analysis of
western blot bands indicated that the expression of Aβ1-42
from the APP + EA group was lower than that in the APP
group (Figure 4C-D). A similar result was detected in the
Con group when compared with the Con + EA group.
These results demonstrate that long-term EA treatment
is an effective method for inhibiting the deposition of
Aβ1-42.EA increased BDNF expression in APP/PS1 double
Tg mice
The results of immunofluorescence with the antibody
specifically recognizing BDNF in the brain showed sig-
nificantly stronger expression in both the hippocampus
and cortex from the EA-treated groups than that in the
non EA-treated groups (Figure 5A-B). Western blot re-
sults also confirmed that the expression of BDNF was
up-regulated in the APP + EA and Con + EA groupscompared with their non EA-treated counterparts
(Figure 5C, P < .05).
EA promoted neurogenesis in APP/PS1 double Tg mice
Survival and differentiation of the newborn cells to neu-
rons (BrdU +Nissl+) were detected 28 days after the last
injection of BrdU. As shown in Figure 6, the result of
BrdU(+) and Nissl(+) cells was consistent with the change
of BDNF expression in the brain. There was a significant
decrease in BrdU(+) and Nissl(+) cells in the APP/PS1
Tg mice groups (including the APP and APP + EA groups)
when compared with the wild-type group (including Con
and Con + EA groups) (P < .05). EA treatment also signifi-
cantly promoted neurogenesis in the APP + EA group, as
well as in the Con + EA group, compared with their non
EA-treated counterparts.
Discussion
AD is a neurodegenerative disease that seriously affects
the quality of life for thousands of patients. There is also
an enormous economic impact of AD for governments.
In Europe, the total costs for dementia in 2008 were es-
timated to be more than 177 billion Euros [15], which
exceeded the costs for patients with either cancer or
cardiovascular diseases [2]. The existing treatments for
AD are unsatisfactory, and searching for an effective
Figure 3 Electroacupuncture suppressed the deposition of Aβ1-42 in the hippocampus and cortex. With immunofluorescence staining
following the EA administration, compared with the APP group, the deposition of Aβ1-42 was significantly decreased in the APP + EA group in
the (A) cortex and (B) hippocampus. Bar = 20 μm.
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major challenge. In the present study, we confirmed the
hypothesis that repeated EA stimulation improved cog-
nitive functioning and reduced the accumulation of Aβ1-42
deposits in the brain. Moreover, the beneficial effects
accompanied with the up-regulation of BDNF expression
and promotion of neurogenesis in the APP/PS1 double
Tg mice, suggest that EA may be a promising treatment
for AD.
In the last two decades, several kinds of genetically
modified mice have been generated as potential models
for studying neurodegenerative processes [16], such as
PDAPP mice reported by Masliah et al. [17] and Tg2575
mice reported by Shi et al. [18]. In the current study, we
chose the model of APP/PS1 double Tg mice, which
were generated by knocking identified familial AD and/
or PS1 into the mice genome; this model has been
widely adopted by other scientists. The APP/PS1 double
Tg mouse was used as the AD model for its aggressive,
early-onset brain amyloidosis, as well as the concurrent
atrophy and substantial cell loss. The clinical relevance
of this model is supported by disturbances of neuronal
structure in the form of dystrophic neurites surrounding
plaques, decreased fiber density, and synaptic dysfunc-
tion that imitates most aspects of AD brain pathology[19,20]. Thus, the APP/PS1 double Tg mouse model is
the closest representative of AD pathology. In this study,
the effectiveness of the Tg mouse model to mimic AD
was evaluated through neurological behavior and path-
ology assessment. Cognitive impairment presented in
7-month-old double Tg mice, and the Aβ deposits in the
hippocampus and cortex were detected in 10-month-old
double Tg mice. These findings indicate that the patho-
logical features of APP/PS1 double Tg mice that mimic
AD remained stable.
Classic and well-known symptoms of AD include prob-
lems with spatial learning and presence of a memory
deficit. Previous studies have shown that EA stimulation
can protect against neuronal damage, and effectively pre-
vent the impairment of learning and memory caused by
cerebral ischemia injury or high-sustained positive acceler-
ation (+Gz) exposures [9,21]. Our study demonstrated that
EA stimulation significantly restored spatial learning and
memory function of AD mice. This suggests that that EA
stimulation may be effective in potentially ameliorating
cognitive impairment caused by AD.
The identification of reliable biomarkers has been hin-
dered by the fact that the diagnosis of AD in clinical prac-
tice depends largely on a patient’s symptoms. However,
increasingly accurate pathological diagnostic methods have
Figure 4 Electroacupuncture suppressed the deposition of Aβ1-42 in the hippocampus and cortex. ELISA test results revealed that Aβ1-42
depositions from the (A) cortex and (B) hippocampus in the APP + EA group and the Con + EA group were significantly lower than those in their
non EA-treated counterparts (n = 5 in each group) (*P < .05 vs. Con group; #P < .05 vs. APP group). (C) Western blot result indicated that the
expression of Aβ1-42 in the Con + EA group was lower than that in Con group. A similar result was detected in the APP + EA group compared with
the APP group. (n = 3 in each group) (*P < .05 vs. Con group; #P < .05 vs. APP group).
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such as APP, Aβ, tau and p-tau, isoprostanes, and inflam-
matory makers. Among these, Aβ deposits are the most
typical pathological sign and a defining factor for cognitive
impairment in AD brains. In the brain, two different kindsFigure 5 Electroacupuncture upregulated the expression of BDNF in
immunofluorescence staining of BDNF (red) and NeuN (green) in the (A) c
in the APP + EA group and Con + EA group compared with their non EA-tr
The protein expression of BDNF was evaluated using western blot. EA sign
wild-type mice compared with their matched counterparts. Data are mean
group). Bar = 20 μm.of Aβ exist (Aβ1-40 and Aβ1-42). Aβ1-42, the metabolite
of the APP and PS1 gene mutation, is a major component
of senile plaques [22-24]. Additionally, the accumulation of
Aβ1-42 in the brain is more cytotoxic than Aβ1-40, in the
context of AD. Aβ is not only a biomarker for diagnosinghippocampus and cortex. Representative double
ortex and (B) hippocampus. With EA treatment, BDNF was upregulated
eated counterparts (*P < .05 vs. Con group; #P < .05 vs. APP group). (C)
ificantly up-regulated the expression of BDNF in the APP/PS1 mice and
s ± SD (n = 5 in each group) (*P < .05 vs. Con group; #P < 0.05 vs. APP
Figure 6 Electroacupuncture enhanced neurogenesis in
hippocampal region of APP mice. (A) Representative
immunofluorescence of BrdU (red) and Nissl (green) staining in the
absence or presence of EA treatment. (B) Quantification of BrdU
+/Nissl + cells in the CA1 and DG region. Data are presented as
means ± SD (n = 5 in each group) (*P < .05 vs. Con group; #P < .05 vs.
APP group).
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tion of an antagonist of Aβ has been shown to improve
memory impairment in APP Tg mice [25]. Thus, re-
searchers are focusing on finding effective methods to
lower Aβ deposits, especially those of Aβ1-42, to reverse
the pathological features of AD. In our study, we demon-
strated that EA treatment was a feasible and effective way
for lowering Aβ1-42 deposits in APP/PS1 mice. However,
the mechanism for EA to reduce Aβ deposit is still unclear
and needing further exploration.
The subventricular zone of the lateral ventricle and
the subgranular layer of the dentate gyrus in the hippo-
campus are two parts associated with adult neurogen-
esis. Dramatic decline in neurogenesis has been proven
to contribute to the impairments of learning and mem-
ory in AD models [26,27]. Some key proteins involved inAD pathogenesis, including apolipoprotein E4 (APOE4),
APP and PS1, have been proved to regulate neurogenesis
[28-30]. Regenerative medicine, which is different from
slowing down or stopping the progression of AD,
may offer a new therapeutic strategy for patients. The
newborn neurons may enhance neuronal plasticity and
integrate into existing neural circuits physically and
functionally [4]. Our results revealed that with BrdU
staining, repeated EA treatment could enhance neuro-
genesis in APP/PS1 Tg mice. The decrease in Aβ1-42
that we mentioned above may be an important factor for
nerve regeneration.
The mammalian neurotrophin family, including nerve
growth factor, BDNF and neurotrophin-3, activates dif-
ferent cell signaling pathways via tyrosine receptor kin-
ase. BDNF localizes in the hippocampus, hypothalamus,
cortex, septum and the adrenergic brain stem nuclei
of the brain and participates in neuron development, dif-
ferentiation and plasticity maintenance throughout life
[31]. BDNF plays an important role in memory forma-
tion and storage by regulating synaptic plasticity. Even if
there have been conflicting results regarding the expres-
sion of BDNF in AD patients [32], most of the results
indicate that BDNF is severely decreased in the hippo-
campus and some cortical areas [7,33]. Meanwhile,
BDNF could reduce cellular damage caused by Aβ1-42
[34]. Our results showed that EA treatment significantly
increased the expression of BDNF in both the hippo-
campus and cortex; this suggests that the increase in
BDNF may be involved in the therapeutic effect of EA
for AD. From our current study, the expression of Aβ
and BDNF changing were also observed in wild-type
mice in. We assumed that the effect of EA on Aβ and
BDNF could be related to a common signaling pathway
but not a specific pathway in AD. Moreover, the control
group was age-matched with the APP mice. Our result
might suggest that electroacupuncture could induce the
protective effect for the central nervous system of aging
and Alzheimer’s disease.
In the present study, we observed that EA stimulation
significantly improved the neurological behavior per-
formance of AD mice, and reduced the deposition of Aβ
in the hippocampus and cortex. At the same time, a no-
ticeable increase in neurogenesis and BDNF expression
in the hippocampus and cortex was also detected. Thus,
our preliminary presumption was that EA stimulation
improved neurobehavioral performance through pro-
moting neurogenesis and BDNF expression in the brain.
However, the link between neurogenesis and the path-
ology of AD is still not fully understood. It is proven
that Aβ deposits impair the transduction path activated
by BDNF such as Ras/ERK, PI3K/Akt and PKA/CREB
[35,36]. Moreover, BDNF is required for long-term
survival of newborn neurons [37]. Presumably, EA may
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neurogenesis, and improve neurobehavior in an AD
model. The precise mechanism of EA treatment for AD
still needs further elucidate.
In addition, Baihui (GV20) acupoint belongs to the Du
series. According to traditional Chinese medical theory,
acupoint of the Du series is the first choice in treating brain
disease. Our previous experimental studies [9-11,38] have
proved that EA at the Baihui acupoint protects brain from
ischemic injury. Thus, we chose the Baihui acupoint in the
present study. Moreover, our previous study [14] also inves-
tigated the specificity of Baihui acupoint in a rat cerebral is-
chemic model. Although in the current paper we aimed to
focus proving that EA owned the possibility for improving
cognitive dysfunction, the specificity for EA treatment in
AD model still need further exploration. This is a limitation
of our study, a sham-acupuncture considered as a control
is necessary for future study.
Conclusions
In summary, the present study demonstrated that EA
stimulation in Baihui (GV 20) acupoint ameliorated learn-
ing and memory deficits and reduced Aβ42 deposit in
APP/PS1 mice. We propose that the underlying mechanism
of EA may be related to the promotion of neurogenesis and
the up-regulation of BDNF expression in the hippocampus
and cortex. These findings provide strong evidence for EA
as a novel strategy for AD treatment.
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